Navigation Links
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Date:5/12/2008

Results show promising neurological recovery in severely-injured, acute

cervical spinal cord injury patients treated with Cethrin

HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after treatment, 38% (5 of 13) of cervical injury patients showed marked recovery of motor and sensory function after treatment as measured by a 2-grade or better improvement in the American Spinal Injury Association, or ASIA, Impairment Scale. Analysis of the data by dose group indicates that Cethrin doses of 1 and 3 mg appear to be the most beneficial for cervical patients with 43% (3 of 7) showing the same 2-grade or better recovery of motor and sensory function.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

"The safety and efficacy observations of the Cethrin trial continue to be encouraging. Many patients have shown a degree of improvement far above the expected outcome," commented Dr. Mark Hurtt, Alseres' Chief Medical Officer. "The interim results of the Phase I/IIa study have helped identify what we believe will be the most effective dose range to carry into our Phase IIb trial later this year."

Based on these results, Alseres intends to move forward with its previ
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
2. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
7. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
(Date:7/23/2008)...July 23 /PRNewswire-USNewswire/ -- The following w...hairman Conyers, Ranking Member Smith, and Members...o testify today., Since I appeared before this Co...better acquainted with the talented and dedicated ...he work they do, and I have come to,appreciate tha...
(Date:7/23/2008)...y 23 /- Dendreon Corporatio... the Independent Data,Monitoring Committee (IDMC) ...overall survival relating to the Company,s Phase 3... Treatment, also known as D9902B) clinical trial,o...any,s investigational,active cellular immunotherap...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 1Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 2Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 3Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 1Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 2Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 1Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 1Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 3
... Profile and Excellent,Pharmacokinetic Properties ...RNewswire/ --,CeNeRx BioPharma, Inc., a clinical s...tive treatments for diseases of the central,nervou...Phase I,clinical trial of Tyrima(TM), its lead can.... In this study, Tyrima was safe and well,tolerate...
...7 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. ...ogy (JACC) has published data from the Ranolazine ... long-term therapy with,Ranexa(R) (ranolazine exte...d in patients with chronic stable angina who compl...led in the ROLE,program. , These data also suggest...
Other Medicine Technology:CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
(Date:7/25/2008)...SNewswire/ -- The following is being,issued by the...ww.newscom.com/cgi-bin/prnh/20080519/DNCLOGO ), M...on Disabilities, and,Bob Kafka, National Organizer...e of John McCain,s appearance via satellite at the...Ohio. There is speculation that Senator,McCain wil...
(Date:7/25/2008)...arter financial results -, LAVAL, QC, July 25 /PR...SDAQ: DDSS) today announced that it will host a co...) to discuss its second quarter 2008,financial res...8 financial,results via news release at approximat...ence call by telephone, dial 416-646-3095 or,1-800...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...e American Society for Gastrointestinal Endoscopy ...opy in the bariatric surgery patient. The rising p...success in surgical interventions led to a marked ...rformed in the U.S., from 13,365 in 1998 to 102,79... preoperative patient and the postoperative patien...
Breaking Medicine News(10 mins):Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...illion women in the United States undergo breast b...umps are benign, //or non-cancerous. But that beni...ne technique is making it easier for women to get ...t cases, benign breast tumors can be left alone. H...
...the final stages of pregnancy seems to increase th...searchers say a diet rich in fish // may boost the...e more fish a woman ate, the less likely she was t...earchers say that low birth weight normally occurs...
...ividuals in lower socioeconomic groups, as measure...ys than those with // higher socioeconomic status,...impact on their health. While those with more educ... not as affected by it. For the study, more than 1...
...h, there is a link between certain types of beddin...recent study show // an association between freque...electric blankets. For the study, synthetic pillow...olyester or Dacron. Quilts of Dacron, polyester or...
Other Medicine News:
...ut patients negative for antinuclear antibodies, w...c diseases such as Systemic lupus erythematosus (L...disease, progressive systemic sclerosis, scleroder...henomenon. They can also be used in conjunction wi...
The PANBIO Inc. Indirect Fluorescence Assay (IFA) for IgG Antinuclear Antibody (ANA) HEp2 is intended for the qualitative and semi-quantitative detection of IgG (Immunoglobulin G) antinuclear antibod
The VerifyNow Clopidogrel Assay measures changes in platelet function in response to patients taking Clopidogrel (Plavix). It uses a specific activator for the P2Y12 pathway, which clopidogrel inhibi
The Wide Angle Twin Mag NP combines the performance of two instruments to deliver unequalled power and versatility into the hands of eye care professionals.
Medicine Products: